Article in Arteriosclerosis, thrombosis, and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
33 authors.
Grigorios PanteloglouInstitute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland.ORCID 0000-0002-7672-7623
Paolo ZanoniInstitute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland.
Christopher S LawCardiovascular Research Institute, University of California, San Francisco (C.S.L., A.K.S.).ORCID 0009-0005-4516-3844
Brian WoodsDivision of Immunology, Boston Children's Hospital, Harvard Medical School, MA (B.W., J.C., R.S.G.).ORCID 0000-0003-4363-4444
Alaa OthmanInstitute of Molecular Systems Biology (A.O.), ETH Zürich, Switzerland.ORCID 0000-0002-0092-5594
Mustafa YalcinkayaInstitute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland.ORCID 0000-0003-2199-0886
Simon F NorrelykkeScientific Center for Optical and Electron Microscopy (S.F.N., A.J.R., S.S., M. Stebler, R.M.), ETH Zürich, Switzerland.ORCID 0000-0001-8302-526X
Andrzej J RzepielaScientific Center for Optical and Electron Microscopy (S.F.N., A.J.R., S.S., M. Stebler, R.M.), ETH Zürich, Switzerland.ORCID 0000-0002-2702-864X
Szymon StomaScientific Center for Optical and Electron Microscopy (S.F.N., A.J.R., S.S., M. Stebler, R.M.), ETH Zürich, Switzerland.
Michael SteblerScientific Center for Optical and Electron Microscopy (S.F.N., A.J.R., S.S., M. Stebler, R.M.), ETH Zürich, Switzerland.ORCID 0009-0009-3552-5185
Anja KerksiekInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Bonn, Germany (A.K., D.L.).ORCID 0009-0002-6162-6106
Michele VisentinDepartment of Clinical Pharmacology and Toxicology (M.V.), University of Zürich and University Hospital Zürich, Switzerland.ORCID 0000-0002-0209-5600
Marieke SmitDepartment of Pediatrics, University Medical Center Groningen, University of Groningen, the Netherlands (M. Smit, J.C.W., J.A.K., B.v.d.S.).ORCID 0009-0009-1449-6186
Justina Clarinda WoltersDepartment of Pediatrics, University Medical Center Groningen, University of Groningen, the Netherlands (M. Smit, J.C.W., J.A.K., B.v.d.S.).ORCID 0000-0003-0066-3720
Sofia KakavaInstitute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland.ORCID 0000-0003-3315-2361
Anton PotapenkoInstitute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland.ORCID 0009-0000-3771-5737
Eveline SchlumpfInstitute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland.ORCID 0009-0000-5432-8552
Silvija RadosavljevicInstitute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland.ORCID 0009-0001-7101-0703
Stephanie HäuslerInstitute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland.ORCID 0009-0005-1401-3640
Marta FutemaCardiology Research Centre, Molecular and Clinical Sciences Research Institute, St George's, University of London, United Kingdom (M.F.).ORCID 0000-0002-2120-2088
Nawar DalilaFaculty of Health and Medical Sciences, Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, University of Copenhagen, Denmark (N.D., A.T.-H.).ORCID 0000-0001-6931-5287
Anne Tybjaerg-HansenFaculty of Health and Medical Sciences, Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, University of Copenhagen, Denmark (N.D., A.T.-H.).
Steve E HumphriesInstitute of Cardiovascular Science, University College London, United Kingdom (S.E.H.).ORCID 0000-0002-8221-6547
Jan Albert KuivenhovenDepartment of Pediatrics, University Medical Center Groningen, University of Groningen, the Netherlands (M. Smit, J.C.W., J.A.K., B.v.d.S.).ORCID 0000-0002-9346-2719
Bart van de SluisDepartment of Pediatrics, University Medical Center Groningen, University of Groningen, the Netherlands (M. Smit, J.C.W., J.A.K., B.v.d.S.).ORCID 0000-0003-3039-4365
Dieter LütjohannInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Bonn, Germany (A.K., D.L.).ORCID 0000-0002-7941-8308
Roger MeierScientific Center for Optical and Electron Microscopy (S.F.N., A.J.R., S.S., M. Stebler, R.M.), ETH Zürich, Switzerland.ORCID 0000-0002-5544-0156
Jérôme RobertInstitute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland.ORCID 0000-0002-2847-9362
Janet ChouDivision of Immunology, Boston Children's Hospital, Harvard Medical School, MA (B.W., J.C., R.S.G.).ORCID 0000-0002-4610-2657
Raif S GehaDivision of Immunology, Boston Children's Hospital, Harvard Medical School, MA (B.W., J.C., R.S.G.).ORCID 0000-0002-6019-3751
Anthony K ShumCardiovascular Research Institute, University of California, San Francisco (C.S.L., A.K.S.).ORCID 0000-0001-5139-4802
Lucia RohrerInstitute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland.ORCID 0009-0003-6681-7021
Arnold von EckardsteinInstitute for Clinical Chemistry (G.P., P.Z., M.Y., S.K., A.P., E.S., S.R., S.H., J.R., L.R., A.v.E.), University of Zürich and University Hospital Zürich, Switzerland.ORCID 0000-0002-1666-2266
Funding
Mechanisms of a Novel Combined Immunodeficiency Caused by a Homozygous Mutation in COPG1R01AI139633 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI GEHA, RAIF SALIM · 2018 to 2022
$3.1M
NIAID NIH HHS R01 AI139633
6 · The paper itself
Abstract
backgroundReverse cholesterol transport by HDLs (high-density lipoproteins) is considered an antiatherogenic metabolic pathway. Hepatocytes are the main contributors to the efficacy of this pathway by the production of apoA-I (apolipoprotein A1) and its lipidation by ABCA1 (ATP-binding cassette transporter A1), selective uptake of cholesterol via SR-BI (scavenger receptor class B type 1), and uptake of entire HDL particles. The molecular determinants of the latter step are not well understood.
methodsWe performed a genome-wide RNA interference screen for genes limiting the uptake of HDL fluorescently labeled at its protein moiety into Huh-7 hepatocarcinoma cells. Top hit genes were validated by targeted in vitro experiments and the analysis of associations between their variants and HDL-C (HDL-cholesterol) levels in the databases of the Global Lipids Genetics Consortium and the UK Biobank, as well as inborn errors of metabolism and their respective mouse models.
resultsThe knockdown of 128 genes significantly inhibited HDL uptake. Six of them encode components of the COPI (coat protein I) coatomer, namely,
conclusionsIn hepatocytes, the COPI coatomer regulates HDL holoparticle uptake, selective lipid uptake, apoA-I secretion, and ABCA1 expression, and thereby, it influences plasma levels of HDL-C.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
COPI Coatomer Regulates Several Steps of HDL Metabolism. · full record | OpenQuestion